Abstract
This study analyzed the US Open Payments and Medicare Part D databases from 2014 to 2022 to assess associations between industry-physician payments and PAH therapy prescribing. Among 5502 pulmonologist-, cardiologist- and pediatrician-prescribers of PAH therapies, drug-specific industry payments were associated with dose-response increases in Medicare spending.